Grace Peace Truong

Grace Truong is an associate in Goodwin’s Intellectual Property Litigation practice and a member of the firm’s Life Sciences Disputes group. She has served clients in matters involving a broad range of technologies, including pharmaceutical sciences, biotechnology, and medical devices. Her experience includes representing life science companies in litigation under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA), other district court patent litigation, unfair import investigations before the U.S. International Trade Commission, and proceedings before the Patent Trial and Appeal Board (PTAB).

Grace has been involved in various stages of patent litigation, including discovery, motion practice, pretrial proceedings, and trial. Some of her recent engagements include:

• Continuous Composites, Inc. v. MarkForged, Inc., No. 21-998-MN (D. Del.) – Representing defendant MarkForged in a patent infringement lawsuit involving 3D printing technology
• Fusion Pharmaceuticals, Inc. v. Universität Heidelberg, IPR2023-00551 (PTAB) – Representing petitioner in IPR related to Actinium-225 radiopharmaceuticals
• Teva Pharmaceuticals International GmbH et al. v. Eli Lilly and Company, No. 18-12029-ADB (D. Mass.) – Representing Teva in asserting method of treatment patents regarding anti-CGRP antibodies against Eli Lilly’s Emgality® (galcanezumab) product
• Certain Pre-Filled Syringes for Intravitreal Injection and Components Thereof, Inv. No. 337-TA-1207 (USITC); Novartis Pharma AG et al v. Regeneron Pharmaceuticals, Inc., No. 20-00690-DNH (N.D.N.Y.); Regeneron Pharmaceuticals, Inc. v. Novartis Pharma AG, et al., IPR2020-01317, IPR2020-01318, IPR2021-00816 (PTAB) – Represented Novartis in ITC investigation, related litigations, and inter partes review proceedings involving assertion of Novartis’s pre-filled syringe patent against Regeneron’s blockbuster EYLEA® (aflibercept) product
• Par Pharmaceutical et al. v. Amneal et al., No. 18-2032-CFC (D. Del.) – Represented Amneal Pharmaceuticals in patent infringement case involving a generic formulation of vasopressin injection
• Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., No. 17-7111 (D. N.J.) –  Represented Dr. Reddy’s in patent infringement litigation concerning Dr. Reddy’s applications to market generic versions of SUBOXONE® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films

Before joining Goodwin, Grace was an IP Litigation summer associate at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.

While in law school, Grace was a student attorney in Harvard Law School’s Veterans Law and Disability Benefits Clinic and a student attorney in the Harvard Health Law and Policy Clinic. She was a line editor for Harvard Journal of Law and Technology and a Student Fellow in the Law, Science, & Technology Program. Grace was also the Events Director for the Harvard Law Entrepreneurship Project. She was awarded the Zuckerman Fellowship from the Harvard Kennedy School of Government for her public service work as a JD/MPH joint-degree student. 

Prior to attending law school, Grace was a Fulbright Fellow and a researcher at the Children’s Hospital of Philadelphia.

Pro Bono

Grace maintains an active pro bono practice, including assisting veterans in VA benefits appeals and representing clients in asylum appeals. 

In 2023, Grace gained significant trial experience during a six-month rotation with the Kings County (Brooklyn) District Attorney’s Office, where she served as a special Assistant District Attorney. During this time, she prosecuted numerous felony cases on behalf of the state of New York, including a jury trial, presentations before the Grand Jury, and several hearings.

While attending Harvard Law, Grace received Dean’s Scholar Prize awards for outstanding work in City Use of Technology and Autonomous Vehicles and Local Government Lab.

Grace is a contributor to Big Molecule Watch, Goodwin’s award-winning blog that reports real-time analysis and updates on regulatory issues, litigation, legislation and other news in the developing world of biosimilars. She is also a regular contributor to Goodwin’s PTAB Trial Tracker. Grace’s recent publications include:

• Co-Author, “Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial,” Goodwin Client Alert, July 2022
• Co-Author, “Five patent issues that European biosimilar developers should consider before entering the US market,” European Pharmaceutical Review, June 2020
• Co-Author, “Call to Change,” Intellectual Property Magazine, April 2020